Oral deferasirox may be an effective iron chelator in patients with thalassaemia and transfusional iron overload

By  

Inpharma, Vol. 1, Iss. 1387, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Pharmacosurveillance and quality of care of thalassaemic patients: A large scale epidemiological survey

By Arboretti R.   Tognoni G.   Alberti D.  

European Journal of Clinical Pharmacology, Vol. 56, Iss. 12, 2001-03 ,pp. : 915-922

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the US: A Literature Review

By Zhang Bin  

PharmacoEconomics, Vol. 29, Iss. 6, 2011-06 ,pp. : 461-474

Adis International

Access to resources Recommend Favorite

Use chelation therapy to reduce iron overload and improve survival in patients with myelodysplastic syndromes

By  

Drugs & Therapy Perspectives, Vol. 27, Iss. 9, 2011-09 ,pp. : 14-17

Adis International

Access to resources Recommend Favorite

Deferasirox dominates deferoxamine for iron overload

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 665, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite